Kaplan–Meier plot of the primary outcome* for A) ELIXA (lixisenatide), B) LEADER (liraglutide), C) SUSTAIN-6 (semaglutide), D) EXSCEL (exenatide), E) Harmony Outcomes (albiglutide), and F) REWIND (dulaglutide) (22–26,28). Insets show the same data on an expanded y-axis. *Death from CV causes, nonfatal MI, nonfatal stroke, or hospitalization for UA for ELIXA; death from CV causes, nonfatal MI, or nonfatal stroke for LEADER, SUSTAIN-6, EXSCEL, Harmony Outcomes, and REWIND. Reproduced from refs. 22–25. ©2015, 2016, and 2017. Massachusetts Medical Society. All rights reserved. Reproduced from ref. 26. ©2018 Elsevier Ltd. All rights reserved. Reproduced from ref. 28. ©2019 Elsevier Ltd. All rights reserved.